Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

160.81 +1.12 (+0.70%)
Streaming Delayed Price Updated: 3:58 PM EDT, Oct 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,176,794
Open 159.92
Bid (Size) 160.81 (4)
Ask (Size) 160.82 (7)
Prev. Close 159.69
Today's Range 159.51 - 161.22
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.96%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Completes Acquisition of V-Wave
From Johnson & Johnson
Via Business Wire
1 Vanguard Index Fund Could Turn $500 Per Month Into a $968,400 Portfolio That Pays $16,000 in Annual Dividend Income
Workers with median earnings can build sizable portfolios that pay hefty amounts of passive income in retirement. 
Via The Motley Fool

Performance

YTD
+0.53%
+0.53%
1 Month
-3.48%
-3.48%
3 Month
+9.36%
+9.36%
6 Month
+5.60%
+5.60%
1 Year
+1.43%
+1.43%

More News

Read More
Should Investors Consider High Yield Dividend Stocks?
Via Talk Markets
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
Via Benzinga
Exposures Product Safety
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio
Via MarketBeat
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
Via Benzinga
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
Via Benzinga
3 Undervalued Dividend Stocks Primed for Growth in 2025
Via MarketBeat
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Via Benzinga
2 Smart Income Stocks to Buy Right Now
Via The Motley Fool
3 Industries Set To Explode When Interest Rates Drop
Via Talk Markets
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Via Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Via Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
Via The Motley Fool
2 Excellent Dividend Stocks to Buy With Less Than $200
Via The Motley Fool
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Via Investor's Business Daily
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
Via Benzinga
For those who appreciate value investing, NYSE:JNJ is a compelling option with its solid fundamentals.
Via Chartmill
Why Masimo Stock Crushed the Market Today
Via The Motley Fool
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Via Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.